{"data":{"id":"us/21-cfr-211.89","jurisdiction":"us","citation":"21 CFR 211.89","heading":"Rejected components, drug product containers, and closures.","body":"Rejected components, drug product containers, and closures shall be identified and controlled under a quarantine system designed to prevent their use in manufacturing or processing operations for which they are unsuitable.","path":["Title 21—Food and Drugs","CHAPTER I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES","SUBCHAPTER C—DRUGS: GENERAL","PART 211—CURRENT GOOD MANUFACTURING PRACTICE FOR FINISHED PHARMACEUTICALS","Subpart E—Control of Components and Drug Product Containers and Closures"],"source_url":"https://www.ecfr.gov/api/versioner/v1/full/2026-08-25/title-21.xml","current_through":"2026-08-25","vintage":"","retrieved_at":"2026-08-27T02:24:47Z","sha256":"41a0e63bb3e9d8c804ca7ac9901caa62f1b98560cb4938c17dee1805d4449d3f","source_id":"us-cfr","stale":true,"prev":"us/21-cfr-211.87","next":"us/21-cfr-211.94"},"notice":"GroundRules: Original legal text. Not legal advice."}